Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Mol Cancer Ther. 2018 Nov 9;18(2):267–277. doi: 10.1158/1535-7163.MCT-18-0478

Figure 3. Tumor growth inhibition by single agent BGB-3111 treatment in MCL subcutaneous (s.c.) and PDX models.

Figure 3.

A, Efficacy of BGB-3111 in Rec-1 s.c. xenograft model (n=10). B, Efficacy of single agent BGB-3111 in MCL PDX model. Vehicle control (n=5); 30 mg/kg BGB-3111 oral gavage BID (n=5). C, Images of resected tumor and spleen from each cohort, as indicated.